Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.650
+0.090 (3.52%)
At close: Sep 26, 2025, 4:00 PM EDT
2.640
-0.010 (-0.38%)
After-hours: Sep 26, 2025, 7:40 PM EDT
Esperion Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Esperion Therapeutics stock ranges from a low of $3.00 to a high of $16. The average analyst price target of $6.50 forecasts a 145.28% increase in the stock price over the next year.
Price Target: $6.50 (+145.28%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +503.77% | Sep 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +503.77% | Jun 17, 2025 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +50.94% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +503.77% | Apr 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +88.68% | Apr 25, 2025 |
Financial Forecast
Revenue This Year
365.13M
from 332.31M
Increased by 9.87%
Revenue Next Year
338.76M
from 365.13M
Decreased by -7.22%
EPS This Year
-0.08
from -0.28
EPS Next Year
-0.02
from -0.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 461.4M | 416.6M | |||
| Avg | 365.1M | 338.8M | |||
| Low | 231.8M | 252.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.8% | 14.1% | |||
| Avg | 9.9% | -7.2% | |||
| Low | -30.2% | -30.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 0.38 | 0.37 | ||
| Avg | -0.08 | -0.02 | ||
| Low | -0.47 | -0.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.